InflaRx's IPO

InflaRx raised a round of funding on November 08, 2017. Investors include Public.

InflaRx is a biopharmaceutical company developing new therapeutics in the terminal complement space. InflaRx focuses on applying its proprietary anti-C5a technology to discover and develop specific in…

Articles about InflaRx's IPO: